363 related articles for article (PubMed ID: 27650916)
1. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.
Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P
Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916
[TBL] [Abstract][Full Text] [Related]
2. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
Mitchell T; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Ching H; Hamdorf J; Adams LA
Am J Gastroenterol; 2018 Oct; 113(10):1484-1493. PubMed ID: 29899440
[TBL] [Abstract][Full Text] [Related]
3. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
[TBL] [Abstract][Full Text] [Related]
4. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease.
Kwon HK; Greenson JK; Conjeevaram HS
Liver Int; 2014 Jan; 34(1):129-35. PubMed ID: 23809459
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
[TBL] [Abstract][Full Text] [Related]
6. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
7. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
8. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD.
Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Hepatol Commun; 2023 Jan; 7(1):e0003. PubMed ID: 36633482
[TBL] [Abstract][Full Text] [Related]
9. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption.
Vilar-Gomez E; Sookoian S; Pirola CJ; Liang T; Gawrieh S; Cummings O; Liu W; Chalasani NP
Gastroenterology; 2020 Sep; 159(3):929-943. PubMed ID: 32454036
[TBL] [Abstract][Full Text] [Related]
10. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
Jamali R; Razavizade M; Arj A; Aarabi MH
World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
12. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study.
Hagström H; Stål P; Hultcrantz R; Brismar K; Ansurudeen I
Scand J Gastroenterol; 2017 Dec; 52(12):1427-1434. PubMed ID: 28927302
[TBL] [Abstract][Full Text] [Related]
13. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
15. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
16. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease.
Björkström K; Stål P; Hultcrantz R; Hagström H
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1461-1468. PubMed ID: 28479500
[TBL] [Abstract][Full Text] [Related]
17. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
[TBL] [Abstract][Full Text] [Related]
18. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.
Ajmera V; Belt P; Wilson LA; Gill RM; Loomba R; Kleiner DE; Neuschwander-Tetri BA; Terrault N;
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1511-1520.e5. PubMed ID: 29378307
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
[TBL] [Abstract][Full Text] [Related]
20. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.
Patel PJ; Smith D; Connor JP; Horsfall LU; Hayward KL; Hossain F; Williams S; Johnson T; Stuart KA; Brown NN; Saad N; Clouston AD; Irvine KM; Russell AW; Valery PC; Powell EE
Can J Gastroenterol Hepatol; 2017; 2017():7927685. PubMed ID: 29226116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
